Fig. 2

Kaplan–Meier overall survival (OS) and relapse-free survival (RFS) curves of intermediate-risk AML patients stratified based on their mutations in DNMT3A a, b, U2AF1 c, d, and EZH2 e, f in the Cleveland Clinic cohort